|Mr. Jonathan Gilbert||Chairman & CEO||N/A||N/A||47|
|Mr. Jonathan James Held CA||Chief Financial Officer||N/A||N/A||32|
|Mr. David Schrader||Chief Operating Officer||N/A||N/A||54|
|Mr. Maghsoud Dariani||Chief Scientific Officer||N/A||N/A||N/A|
Scythian Biosciences Corp. engages in the research and development of cannabinoid-based combination drug therapies for the treatment of concussions and traumatic brain injury. It also develops drug candidates for the treatment of gastro-intestinal inflammatory issues. The company is headquartered in Toronto, Canada.
Scythian Biosciences Corp.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.